PRA announced the recent creation of a legal entity in Bulgaria to support continued growth and expand operations in the Balkan area. Located in Sofia, the new entity will enhance PRA’s local presence, provide a solid base for growth, and strengthen PRA’s ability to provide professional quality clinical services in Bulgaria and neighboring countries.
PRA began operating in Romania and Greece in 2006, and demand for services in the Balkan region has steadily increased and expanded to Turkey and Bulgaria. PRA's staff has grown accordingly and the number of feasibilities and awarded projects nearly tripled in the past year alone.
“In addition to our presence in the Central and Eastern European region, PRA’s new entity in Bulgaria is a part of our strategic growth and development that clearly demonstrates our commitment to expansion,” said Dr. Ludger Langer, PRA’s Vice President of Clinical Operations in Europe, Asia-Pacific and Africa.
The legal entity in Bulgaria further demonstrates our commitment to meeting the expanding needs of our clients in an ever-changing clinical trials environment and provides our local teams with a local corporate basis for operations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.